|View printer-friendly version|
In connection with the sale of the Series A Preferred Stock,
Additional Information Concerning Series A Preferred Stock
In addition to the preferred dividend, the Series A Preferred Stock will be entitled to participate with
All outstanding Series A Preferred Stock will automatically be converted into common shares on
The Series A Preferred Stock will be entitled to vote with common shares on all matters submitted to common share holders for approval. Each share of Series A Preferred Stock will be entitled to a number of votes equal to the number of common shares into which it could then be converted. The Series A Preferred Stock will also vote as a separate class on certain matters affecting those shares.
In the event of a liquidation or dissolution of
The securities described above have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in
This communication is not an offer to sell, or a solicitation of any offer to buy any securities, any securities in any state or jurisdiction where the offer or sale is not permitted.
Asterias Biotherapeutics, Inc.is a new subsidiary which has acquired the stem cell assets of Geron Corporation, including patents and other intellectual property, biological materials, reagents and equipment for the development of new therapeutic products for regenerative medicine. OncoCyte Corporationis developing products and technologies to diagnose and treat cancer. Cell Cure Neurosciences Ltd.(“Cell Cure Neurosciences”) is an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of macular degeneration, and treatments for multiple sclerosis. LifeMap Sciences, Inc.(“LifeMap Sciences”) markets, sells and distributes GeneCards®, the leading human gene database, as part of an integrated database suite that also includes the LifeMap Discovery® database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database. ES Cell International Pte Ltd., a Singaporeprivate limited company, developed clinical and research grade hES cell lines and plans to market those cell lines and other BioTimeresearch products in over-seas markets as part of BioTime’s ESI BIO Division. BioTime Asia, Limited, a Hong Kongcompany, may offer and sell products for research use for BioTime’s ESI BIO Division. OrthoCyte Corporationis developing therapies to treat orthopedic disorders, diseases and injuries. ReCyte Therapeutics, Inc.is developing therapies to treat a variety of cardiovascular and related ischemic disorders, as well as products for research using cell reprogramming technology.
Additional information about
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for
To receive ongoing